Background:
Celiac disease (CD) is a chronic, systemic immune-mediated condition triggered by gluten exposure in genetically predisposed individuals and characterized by intestinal inflammation, mucosal injury, and impaired nutrient absorption. Lifelong adherence to a strict gluten-free diet remains the cornerstone of treatment, yet inflammatory and gastrointestinal manifestations may persist despite dietary adherence.
Curcumin has anti-inflammatory and antioxidant properties and may modulate T-cell activation, antigen-presenting cell function, inflammatory signaling, oxidative stress, intestinal barrier integrity, and gut microbial balance. This pilot randomized controlled trial was designed to investigate whether adjunctive nano-curcumin can improve disease-related clinical manifestations and inflammatory biomarkers in children with CD.Methods: This prospective, single-center, double-blind, placebo-controlled, parallel-group pilot trial will be conducted at Akbar Children's Hospital, Mashhad, Iran. Thirty eligible children aged ۵–۱۸ years with celiac disease of less than six months' duration will be randomly allocated in a ۱:۱ ratio to nano-curcumin (۸۰ mg/day) or matched placebo for ۱۲ weeks while receiving a gluten-free diet. The two primary outcomes are changes from baseline to week ۱۲ in fecal calprotectin and serum tissue transglutaminase IgA (tTG-IgA). Secondary outcomes are gastrointestinal symptoms measured by the Gastrointestinal Symptom Rating Scale (GSRS) and standardized anthropometric measures. The primary analysis will use baseline-adjusted analysis of covariance (ANCOVA); logarithmic transformation will be considered for markedly right-skewed positive biomarker values. Because this is an exploratory pilot trial, the study is not powered to provide definitive evidence of efficacy.Conclusion: This pilot trial will evaluate the feasibility and preliminary effects of adjunctive nano-curcumin on gastrointestinal symptoms and inflammatory and serological outcomes in children with newly diagnosed CD receiving a gluten-free diet. The study is intended to generate preliminary estimates of treatment effects and outcome variability rather than establish definitive clinical efficacy. Its findings may provide an empirical basis for the design of a subsequent adequately powered randomized controlled trial.Trial registration: Iranian Registry of Clinical Trials IRCT۲۰۲۴۰۷۲۱۰۶۲۵۰۱N۱. Registered on October ۱۹, ۲۰۲۴.